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doi:10.1016/j.ejvs.2010.08.022Abstract Objectives: Abdominal aortic aneurysms (AAAs), being predominantly atheroscle-
rotic in nature, have underlying inflammatory activity. As it is well established that ultrasmall
superparamagnetic iron oxide (USPIO) particles accumulate in the macrophages within ather-
omatous lesions, USPIO-enhanced magnetic resonance (MR) imaging can be potentially effec-
tive in the quantification of the associated inflammatory processes.
Methods: A total of 14 patients underwent USPIO-enhanced MR imaging using a 1.5T-MR system.
Quantitative T2* and T2 relaxation time data were acquired before and 36 h after UPSIO infusion
at identicalAAA locations.Thepre-andpost-USPIO-infusionrelaxation times (T2* andT2)werequan-
tified and the correlation between pre- and post-USPIO infusion T2* and T2 values was investigated.
Results: There was a significant difference between pre- and post-infusion T2* and T2 values (both
respective p-valuesZ 0.005). A significant correlation between T2* and T2 values post-USPIO infu-
sion was observed (rZ 0.90, p < 0.001), which indicates USPIO uptake by the aortic wall.
Conclusions: Aortic wall inflammation using USPIO-enhanced MR imaging is feasible. Use of quanti-
tative T2 and T2* pulse sequences provides a quantitativemethod for assessing USPIO uptake by the
aortic wall.
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168 U. Sadat et al.Atherosclerosis, which was previously considered a bland associated inflammatory processes. However, very little is
lipid-storage disorder, can present as a chronic inflamma-
tory disease, which proceeds in the context of enhanced
plasma lipid levels.1 Various cellular and molecular imaging
techniques allow visualisation of these underlying inflam-
matory processes.2e6 These offer new opportunities to
study the evolution and biology of atherosclerotic lesions in
vivo, as well as new clinically translatable strategies to
identify high-risk atherosclerotic lesions and potentially to
monitor the efficacy of anti-inflammatory medications,
which are used to treat atherosclerosis.7
Ultrasmall superparamagnetic iron oxide (USPIO)-
enhanced magnetic resonance (MR) imaging is one of these
imaging techniques, which has been successfully used to
identify inflammation within carotid atheroma,8e11 and
also to monitor the anti-inflammatory effect of a statin on
carotid plaque stabilisation.12 USPIO particles are believed
to be taken up by the macrophages within atherosclerotic
plaques, thus producing a T2*-susceptibility effect visible
as signal voids (hypointense regions) in T2*-weighted
images.5 T2* represents the characteristic time of trans-
verse relaxation in the presence of magnetic field inho-
mogeneities. Magnetic field inhomogeneities arise from
inherent imperfections in the field produced by the
magnet, as well as susceptibility differences within the
body and accelerate the decay of the transverse magnet-
isation. The degree and extent of USPIO-induced signal
loss is related to the severity of the inflammation,13 with
vulnerable atherosclerotic lesions exhibiting higher
USPIO-defined inflammation compared with stable ones.14
Quantitative T2* measurements have recently been
shown to be more robust than other semi-quantitative
methods (based on relative signal intensity measurements),
previously used to assess USPIO uptake.15 In addition,
quantitative T2 measurements have been suggested to be
more specific than T2* relaxation, due to their inherent
insensitivity to concomitant magnetic field inhomogenei-
ties16 (T2 is the characteristic time of spinespin relaxation
in the transverse plane). T2 only depends on the exchange
of energy with nearby nuclei, while T2* is additionally
affected by magnetic field inhomogeneity. Therefore, T2*
has a potential weakness in that it might not accurately
reflect iron concentration in tissue because of its sensitivity
to shimming and susceptibility. T2 is potentially more
specific, but has a lower sensitivity. Initial attempts to
quantify iron deposition in vivo using T2 were unsuccessful,
mainly due to hardware limitations and problems related to
motion artefacts. By contrast, T2* measurements have
increasingly been used in clinical practice because of their
sensitivity to iron and good reproducibility. Recently,
robust quantitative T2 sequences
17 have become available,
which substantially reduce acquisition times with respect
to standard spin echo acquisitions. It should also be noted
that the image quality and signal-to-noise ratio (SNR) are
superior in the quantitative T2 sequence. For this reason,
we decided to measure both T2 and T2* as both have the
potential of being used to quantify USPIO uptake.
Because abdominal aortic aneurysms (AAAs) are mostly
atherosclerotic in nature and have underlying inflammatory
activity,18 USPIO-enhanced MR imaging can potentially be
effective in the visualisation and quantification of theknown about USPIO uptake in the aortic wall.19,20 Tradi-
tionally, aortic diameter has been used for the clinical
assessment of patients with large aneurysms to identify
those at higher risk of rupture. However, small aneurysms
also rupture.21,22 Therefore, USPIO-enhanced MR imaging
could be used to assess inflammatory activity within aneu-
rysms, which although small in size, may have higher
inflammation and, therefore, be more prone to rupture. In
this study, we assess whether USPIO uptake in AAAs can be
quantified using both T2*- and T2- relaxationmeasurements.
Methods
Fourteen patients with an infra-renal AAA were recruited
from the Cambridge Vascular Unit. All patients were
undergoing serial ultrasound imaging of their AAAs as part
of the UK-based AAA screening programme. The research
project had ethics approval from the Regional Research and
Ethics Committee and the Medicines and Healthcare prod-
ucts Regulatory Agency (MHRA). All patients gave written
informed consent.
The inclusion criteria for the study were:
(1) patient age 18e90 years;
(2) known infra-renal AAAs (>4.0 cm to <5.5 cm), under
regular surveillance;
(3) not being considered for surgery or endovascular
treatment; and
(4) subjects must give signed written informed consent
before beginning study-related procedures.
The exclusion criteria included:
(1) history of atopy, asthma, allergic reaction to contrast
materials and allergy to iron and dextran;
(2) documented history of renal impairment (estimated
glomerular filtration rate <60 ml min1 1.73 m2);
(3) documented history of haemochromatosis; and
(4) contraindication to MR imaging such as metallic joint
replacements and cardiac pacemaker.Pre-USPIO infusion MR imaging
MR images before and after USPIO infusion were acquired
using a 1.5T-MR system (Signa HDx, GE Healthcare, Wauke-
sha, WI, USA) and an eight-channel phased-array cardiac
coil. Axial and coronal fast imaging employing steady-state
acquisition (FIESTA) images covering the infra-renal AAA
(slice thickness: 6 mm) were acquired to identify the aneu-
rysm shoulder (defined as the site where the normal aorta
joins the aneurysmal section), which is believed to be
a location of maximum structural weakness.23e28 A two-
dimensional (2D), fat-suppressed, single breath-hold, double
inversion recovery (DIR)-prepared fast spin echo (FSE) pulse
sequence effective echo time (TEeff) Z 6.7 ms; repetition
time (TR)Z 1 RR; echo train length (ETL)Z 12was used to
produce 3e5 axial T1-weighted images covering the aneu-
rysm shoulder (voxel size Z 0.625  0.625  5 mm).
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shoulder at the same slice location as T1-weighted images,
with no inter-slice gap, using a 2D, ECG-triggered, single
breath-hold, multi-echo, segmented k-space fast gradient
echo pulse sequence (MFGRE, GE Healthcare,Waukesha,WI,
USA) which was modified in-house to include DIR prepara-
tion. Eight echoes, with TEs ranging from 3.2 ms to 41 ms at
5.4 ms increments were acquired. The TEs for the T2*
acquisition were selected on the basis of prior T2*
measurements performed in carotid plaques pre- and post-
USPIO infusion.15 Other imaging parameters were:
TRZ 1RR; flip angleZ 20; slice thicknessZ 5mm;matrix
size Z 2562; views-per-segment Z 8. Quantitative T2 data
were acquired at the same slice location as T1-weighted
images, using a prototype 2D DIR-prepared, single breath-
hold multi-echo FSE pulse sequence (MEFSE, GE Healthcare,
Waukesha, WI, USA). Four echoes with TEs at 4.5, 22.5, 40.8
and 58.8 ms were acquired. Other imaging parameters were
TR Z 1  RR; ETL Z 16; slice thickness Z 5 mm; matrix
sizeZ 256  192; parallel imaging acceleration factorZ 2.
The reason for using 5-mm slice thickness was that because
the aorta was located approximately midway between the
twocoil elements, imageswere intrinsically characterisedby
low SNR. A thinner slice thicknesswould have reducedpartial
voluming effects in the slice-select direction at the expense
of a reduction in SNR. A 5-mm slice thickness was considered
as a good compromise to produce relatively high-SNR images
while ensuring limited partial voluming effects in the slice-
select direction. The imaging field of view for the T2* and T2
acquisitions was chosen on a per patient basis and ranged
between 24 and 42 cm.USPIO infusion
Following the baseline MR imaging of AAA, patients were
given an infusion of Sinerem (Guerbet, Roissy, France),
a USPIO contrast agent. The compound was supplied as
a dry powder and initially made up to a volume of 15 ml
with normal saline. An appropriate weight-calculated
dose was then measured. The dose used was 2.6 mg
Fe kg1. The contrast agent was further diluted in 100 ml
of normal saline and given as a slow infusion through
a large-bore intravenous cannula over a period of 30 min.
Safety data for this contrast agent have previously been
published.12Figure 1 An axial MR slice with 6 regions of interest (ROIs)
drawn on it. There were 3e5 ROIs per patient, depending on
the number of slices (N) used to cover the aneurysm shoulder.
In the segmental analysis, each ROI was divided into 6
segments so that 6  N segments were analysed for each
patient. Maps and histograms were produced for each ROI so
that the number of maps/histograms per patient was equal to
the number of slices used to cover the aneurysm shoulder. In
the statistical analysis, we always considered a single metric
per patient so that no correction was necessary. In the
segmental analysis, we considered the average T2 and T2*
values over all the segments and slices for each patient. In the
histogram analysis, the average median value over the three
slices was considered.Post-USPIO infusion MR imaging
AAA MR imaging was repeated 36 h following USPIO infu-
sion. The optimum time window for MR imaging post-USPIO
infusion has been previously determined to be between 36
and 48 h.29 Post-infusion T1-weighted, T2) and T2 images
were acquired at the same AAA locations as for the base-
line MR imaging. Slice locations between pre- and post-
USPIO infusion were matched taking the distance from the
renal arteries or the aortic bifurcation as a reference. A
Modified Look Locker Inversion recovery (MOLLI) sequence
was used to obtain quantitative T1 measurements of the
blood pool post-infusion to optimise the inversion time (TI)
in the DIR-prepared pulse sequences,30 due to thereduction in the T1 of blood following USPIO infusion. The
other imaging parameters were chosen to match the
baseline MR imaging.
MR image analysis
Images were analysed with software developed in-house
using Matlab version 7.5.0 (The Mathworks, Inc., Natick,
MA, USA). Regions of interest (ROIs) delineating the wall/
lumen interface and the external aneurysmal wall were
manually drawn on T2 images pre- and post-USPIO infusion.
The same ROIs were copied to the corresponding T2*
images. Both T2* and T2 images were analysed on
a segmental basis whereby each ROI was divided into six
radial segments (Fig. 1). For each segment, the mean signal
intensity for each echo time was measured and plotted as
a function of the echo time to obtain a signal decay curve.
The Miller correction, to account for non-zero background
signal intensity,31 and a non-linear curve-fitting algorithm32
were used to fit an exponential decay model to each data
set to derive the proton density (M0) and corresponding T2*
or T2 relaxation times. A similar analysis was performed on
a per-pixel basis to produce T2* and T2 maps and histo-
grams over each ROI.
Table 1 Patient demographics (n Z 14) reporting
mean  standard deviation.
Patient demographics mean SD
Age [yrs] 75  7
Hypertension [%] 6  46
Diabetes [%] None
Renal impairment [%] None
Peripheral vascular Disease [%] 3  23
Ischaemic heart disease [%] 6  46
Current Smokers [%] 6  46
Ex-smokers [%] 7  54
Heart Rate [beats/min] 68  10
Systolic blood pressure mmHg
[mmHg]
138  26
Diastolic blood pressure mmHg
[mmHg]
80  10
AAA growth rate [mm/yr] 3.93  2.53
Patients on aspirin (dose: 75 mg
per day)
100%
Patients on statins [mean dose Z 40 mg
(Simvastatin equivalent)]
100%
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Normally distributed summary data are reported as
mean  standard deviation. Differences between T2* and
T2 pre- and post-infusion were assessed by a paired two-
sided t-test or a Welch test when variances were different
according to the F-test. Spearman’s correlation coefficients
were used to measure the strength of correlation between
T2* and T2 pre- and post-USPIO infusion. Simple linear
regression was used to determine the relationship between
DT2* and DT2 and the aneurysm growth rate. A p-value of
less than 0.05 was considered statistically significant. The
analysis was performed using the statistical programming
language R version 2.5.1 (The R Foundation for Statistical
Computing, Vienna, Austria).
Results
Of the 14 patients recruited, 13 patients successfully
completed the study and were included in data analysis.Figure 2 Box and whisker plots of the average T2 (a) and T2* (b)
and post-infusion were significantly different (p Z 0.005). The samOne T2* data set pre-USPIO and three T2* data sets post-
infusion were discarded due to poor image quality. T2 data
sets (pre- and post-infusion) of all 13 patients had good
image quality and were used for analysis. The average age
of the patients was 75  7 years. The majority of the
patients were male (n Z 12, 92%). The patient demo-
graphics are presented in Table 1. The average imaging
time was 40  8 min for the first MR session and 50  15 min
for the second MR imaging session. The second imaging
session included the MOLLI sequence to obtain quantitative
T1 measurements of the blood pool post-infusion and
acquisition of additional scout images to ensure co-local-
isation with respect to the first imaging session. This
explains the slightly longer imaging time in the second visit.
Segmental T2* and T2 values pre- and post-USPIO
infusion were significantly different (both respective
p-values Z 0.005; pre-infusion T2* Z 37.8  13.5 ms;
T2 Z 56.4  14.7 ms; post-infusion T2* Z 20.4  8.8 ms;
T2 Z 35.8  13.8 ms). The median T2* and T2 as deter-
mined from the per-slice histogram analysis also changed
significantly following USPIO infusion (both respective
p-values Z 0.005). Distributions of the average T2 and T2*
values over the six segments pre- and post-infusion are
shown in Fig. 2(a) and (b), respectively.
No correlation between segmental T2* and T2 values
either pre- or post-infusion was found; however, the
histogram analysis revealed a significant correlation
between T2* and T2 values post-infusion, but no correlation
between the corresponding values pre-infusion when
comparing the histograms median values (pre-infusion:
r Z 0.27; p-value Z 0.44; post-infusion: r Z 0.90; p-value
<0.001; Fig. 3). Two of the 14 patients, who participated in
the study, had intraluminal thrombus (ILT). Figs. 4 and 5
show the T1-weighted images and the first echoes from
the T2 and T2* acquisitions pre- and post-infusion as well as
the corresponding T2 maps and FIESTA images. The case
reported in Fig. 4 shows a significant reduction in T2 values
within the ILT, suggesting a higher degree of USPIO uptake
and, hence, inflammation in this region than in the adja-
cent aortic wall. By contrast, the case shown in Fig. 5,
while characterised by a small T2 variation between pre-
and post-infusion, showed a marked T1 effect (hyper-
intensity) on T1-weighted images, which probably reflects
a relatively lower degree of USPIO uptake.33values over the 6 segments pre and post-infusion. T2 values pre
e was true for T2* values (p Z 0.005).
Figure 3 Correlation between the cross-sectional median
T2* and T2 values as derived from the histogram analysis.
There was no correlation between T2* and T2 values pre-USPIO
infusion (black circles). A significant correlation was found
between T2* and T2 values post-USPIO infusion (red triangles,
Spearman’s correlation coefficient Z 0.90 [p-value < 0.001]).
Similar results were obtained when considering the histogram
mean and mode values.
Figure 4 T1-weighted images and first echoes from the T2* and T
T2 maps and FIESTA images. T2 values following USPIO infusion we
region characterised by the greatest T2 change was approximately
a high degree of USPIO uptake and hence inflammation in this regi
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As degradation of the extracellular matrix within the aortic
wall is responsible for the ‘terminal event’ of AAA
rupture,34 visualisation/quantification of the associated
aortic wall inflammatory activity could potentially be used
for the rupture-risk assessment of AAAs. USPIO-enhanced
MR imaging has been used extensively for the assessment of
the underlying inflammatory activity in atherosclerotic
plaques,5 and also seems to have the potential for inves-
tigating the aetiopathology of AAA.19,35e37 In this study, for
the first time, USPIO uptake by the AAA wall was quantified
using both T2* and T2 relaxation measurements. Previously,
Truijers et al. have reported the use of USPIO-enhanced MR
imaging for the assessment of inflammation in the human
aortic wall.20 However, they acquired MRI data post-USPIO,
and performed a semi-quantitative analysis technique.
which involved counting the number of quadrants charac-
terised by USPIO-induced signal loss as a marker of
inflammation. Whilst similar semi-quantitative approaches
have been widely employed, they have been criticised in
a recent editorial, which highlights problems associated
with interpreting a semi-quantitative metric as a meaning-
ful pseudo-marker for inflammation.38 An alternative
approach is to quantify the change in T2* relaxation time of
the aortic wall directly, by multi-echo gradient echo
imaging. USPIO uptake by activated macrophages within2 acquisitions pre and post-infusion as well as the corresponding
re considerably lower than T2 values pre-USPIO infusion. The
coincident with the thrombus region (black arrow), suggesting
on, compared to the adjacent aortic wall (white arrow).
172 U. Sadat et al.the inflamed tissue produces a localised susceptibility
artefact, which can be quantified in terms of T2* short-
ening. Although T2* relaxivity is more sensitive to varia-
tions in USPIO concentration, this technique has previously
received criticism due to its intrinsic sensitivity to magnetic
field inhomogeneities. Which. in principle. can lead to
inaccurate T2*measurements.
39 In this study, we measured
both T2 and T2* relaxivities and found them to be signifi-
cantly correlated post-USPIO infusion. This confirmed
previous work by He et al.16 who reported a strong linear
correlation between myocardial T2 and T2* values in
iron-overloaded patients, and no correlation in healthy
volunteers. Likewise, the post-USPIO-infusion correlation
between T2 and T2* values observed in our study indicates
USPIO uptake within the aortic wall.
We did not observe any correlation between the
segmental T2 and T2* values pre- and post-infusion. There
was no correlation pre-infusion, as there is not a common
dominating factor in determining T2 and T2* values. The
reason why we did not find any correlation between
segmental T2 and T2* values post-infusion is probably
a consequence of assuming normally distributed values
within each segment. The histogram analysis showed that
T2* values were not normally distributed due to the pres-
ence of outliers produced by artefacts in the original
MFGRE images. When considering the histograms medianFigure 5 T1-weighted images and first echoes from the T2* and T
T2 maps and FIESTA images. Unlike the case reported in Figure 3, T
low USPIO-defined inflammation in the thrombus (black arrow) in th
confirmed by the presence of a marked T1 effect (hyperintensity lin
images.values, more representative of the underlying actual
distribution, a significant correlation was found between T2
and T2* values post-USPIO infusion. Histograms were
produced to allow further investigation of the distribution
of T2 and T2* values on a per-slice basis.
We also observed that the over all image quality of the
MEFSE pulse sequence was superior to that of the MFGRE
sequence with fewer outliers in the resulting T2 and T2*
values. This is probably because the MEFSE pulse sequence
is inherently insensitive to field inhomogeneities. Although
T2 is less sensitive to variations in USPIO concentrations,
the T2 reduction between pre- and post-imaging sessions
was still significant. These features probably make MEFSE
the preferred pulse sequence for quantitative USPIO
imaging.
As mentioned in the results, a T1 effect was observed
following USPIO imaging, we did not attempt any quanti-
tative T1 measurement in this study. However, recent
experiments performed by our group in USPIO-containing
gels showed that, at low concentrations of USPIO, there is
an observable increase in signal intensity attributed to the
USPIO nanoparticles shortening the T1 relaxation time of
protons in the vicinity of the USPIO nanoparticles. As the
concentration of USPIO increases further, T2* dephasing
starts to dominate, and there is an observable decrease in
signal intensity.15 This effect was responsible for the signal2 acquisitions pre and post-infusion as well as the corresponding
2 maps pre and post-infusion were relatively similar, reflecting
is patient. The limited USPIO uptake observed in this case was
ing the thrombus shown by white arrow) visible on T1-weighted
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plaques after USPIO infusion.33 The case shown in Fig. 5 was
characterised by a small T2/T2* variation between pre- and
post-infusion measurement, suggesting a low degree of
USPIO uptake. This was further confirmed by the localised
signal enhancement in proximity to the fibrous cap visible
on both T2- and T2*-weighted images, which, due to the TR
of 1  RR, also had some degree of T1 weighting, thus
explaining the signal hyperintensity.
In general, we also observed excellent patient compli-
ance, with none of the patients having any USPIO-infusion-
related adverse effects. Although the breath-holds used for
the MR pulse sequences varied from 8 to 30 s, none of the
research subjects withdrew from the study due to poor
compliance. Only one patient withdrew from the study
after the pre-USPIO imaging, and this was due to general
frailty.
We believe this study to be the first to report quantita-
tive T2* and T2 relaxation times pre- and post-USPIO in
AAA, and as a feasibility study, it provides useful informa-
tion, which can be used for planning large-scale studies in
future, aimed at imaging inflammation within the aortic
wall with novel agents. However, it has some limitations.
One limitation is the lack of histology; but obtaining
reliable MR image co-registration or correlation with
histological sections would require excision of the entire
aneurysm (aneurysmectomy), which is not routinely per-
formed in clinical practice. Using punch or wedge biopsies
to get histological information may not provide useful data
for MR image correlation purposes because the general
heterogeneity of USPIO uptake as shown in the T2 maps
demonstrates how difficult it would be to sample an
appropriate region. Second, as USPIO can be taken up by
the lymph nodes (such as periaortic lymph nodes), due to
close proximity of the periaortic lymph nodes to the aortic
wall, blooming (resulting from T2)) may impair the
discrimination between signal loss in atherosclerotic pla-
ques and signal loss from the lymph nodes. However, we did
not observe this in our patients. Lastly, the USPIO agent
used in this study is no longer commercially available.
However, the technical development done in this study can
be used in future studies using other USPIO agents, which
are being developed.
Conclusions
Imaging aortic wall inflammation using UPSIO-enhanced MRI
is clinically feasible. Use of quantitative T2 and T2* pulse
sequences provides a quantitative method for assessing
USPIO uptake by the aortic wall, which is suggestive of
underlying inflammation within abdominal aortic aneu-
rysms. Future studies should focus on using these imaging
protocols to assess the relationship between aneurysm
expansion and USPIO-defined inflammation in larger patient
cohorts. This may help us assess the efficacy of various anti-
inflammatory medications in doseeresponse studies in
future. The effectiveness and use of USPIO-enhanced MR
imaging in routine clinical practice remains to be estab-
lished compared with the standard clinical follow-up and
duplex ultrasound screening.Conflict of Interest
None.
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